Hypoxic radiosensitization: adored and ignored
10.1200/jco.2007.12.7878 · doi-reference
Radioprotection in normal tissue and delayed tumor growth by blockade of CD47 signaling
10.1126/scitranslmed.3000139 · doi-reference
Thrombospondin-1 and CD47 limit cell and tissue survival of radiation injury
10.2353/ajpath.2008.080237 · doi-reference
Inhibitors of angiogenesis: new hopes for oncologists, new challenges for anesthesiologists
10.1097/aln.0b013e3181ed098d · doi-reference
Increasing survival of ischemic tissue by targeting CD47
10.1161/01.res.0000259579.35787.4e · doi-reference
Regulation of nitric oxide signalling by thrombospondin 1: implications for antiangiogenic therapies
10.1038/nrc2561 · doi-reference
Phase II study of nitric oxide donor for men with increasing prostate-specific antigen level after surgery or radiotherapy for prostate cancer
10.1016/j.urology.2009.03.004 · doi-reference
Effect of nitric-oxide synthesis on tumour blood volume and vascular activity: a phase I study
10.1016/s1470-2045(07)70001-3 · doi-reference
5-Nitroimidazoles. II: Unexpected reactivity of ronidazole and dimetridazole with thiols
10.1139/v93-174 · doi-reference
Changes in tumor oxygenation/perfusion induced by the no donor, isosorbide dinitrate, in comparison with carbogen: monitoring by EPR and MRI
10.1016/s0360-3016(00)00694-5 · doi-reference
Radiosensitization of HT-29 cells and xenografts by the nitric oxide donor DETANONOate
10.1002/jso.21318 · doi-reference
Novel therapeutic applications of nitric oxide donors in cancer: roles in chemo- and immunosensitization to apoptosis and inhibition of metastases
10.1016/j.niox.2008.04.018 · doi-reference
Chemosensitization of cancer in vitro and in vivo by nitric oxide signaling
10.1158/1078-0432.ccr-06-1807 · doi-reference
Effects of diethylamine/nitric oxide on blood perfusion and oxygenation in the R3230Ac mammary carcinoma
10.1038/bjc.1997.406 · doi-reference
Dual role of NO donors in the reversal of tumor cell resistance and EMT: downregulation of the NF-κB/Snail/YY1/RKIP circuitry
10.1016/j.niox.2010.10.001 · doi-reference
Nitric oxide: NO apoptosis or turning it ON?
10.1038/sj.cdd.4401261 · doi-reference
Nitric oxide stimulates Ca(2+)-independent synaptic vesicle release
10.1016/0896-6273(94)90440-5 · doi-reference
Nitric oxide and S-nitrosylation: excitotoxic and cell signaling mechanism
10.1016/s0248-4900(03)00004-2 · doi-reference
Therapeutic potential of nitric oxide in cancer
10.1016/j.drup.2006.05.003 · doi-reference
Solution structure of a nitrous acid induced DNA interstrand cross-link
10.1093/nar/gkh606 · doi-reference
A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors
10.1007/s00280-009-1188-1 · doi-reference
Oxygen dependence and extravascular transport of hypoxia-activated prodrugs: comparison of the dinitrobenzamide mustard PR-104A and tirapazamine
10.1016/j.ijrobp.2007.05.049 · doi-reference
The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3
10.1158/0008-5472.can-09-3237 · doi-reference
Radiosensitising agents for the radiotherapy of cancer: advances in traditional and hypoxia targeted radiosensitisers
10.1517/13543770902824172 · doi-reference
Inhibition of both thioredoxin reductase and glutathione reductase may contribute to the anticancer mechanism of TH-302
10.1007/s12011-009-8544-1 · doi-reference
Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug
10.1182/blood-2010-02-269126 · doi-reference
Potent and highly selective hypoxia-activated achiral phosphoramidate mustards as anticancer drugs
10.1021/jm701028q · doi-reference
Phase I clinical trial of survivin-derived peptide vaccine therapy for patients with advanced or recurrent oral cancer
10.1111/j.1349-7006.2010.01789.x · doi-reference
XIAP and survivin as therapeutic targets for radiation sensitization in preclinical models of lung cancer
10.1038/sj.onc.1207929 · doi-reference
Proliferating cell nuclear antigen, survivin, and CD34 expressions in pancreatic cancer and their correlation with hypoxia-inducible factor 1alpha
10.1097/01.mpa.0000202961.71600.9b · doi-reference
IAP proteins: blocking the road to death's door
10.1038/nrm830 · doi-reference
The selective hypoxia inducible factor-1 inhibitor PX-478 provides in vivo radiosensitization through tumor stromal effects
10.1158/1535-7163.mct-08-0981 · doi-reference
Radiosensitization and stromal imaging response correlates for the HIF-1 inhibitor PX-478 given with or without chemotherapy in pancreatic cancer
10.1158/1535-7163.mct-09-0768 · doi-reference
Results from a phase I, dose-escalation study of PX-478, an orally available inhibitor of HIF-1a
10.1200/jco.2010.28.15_suppl.3076 · doi-reference
Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1alpha
10.1158/1535-7163.mct-07-0463 · doi-reference
Treatment with HIF-1alpha antagonist PX-478 inhibits progression and spread of orthotopic human small cell lung cancer and lung adenocarcinoma in mice
10.1097/jto.0b013e3181dc211f · doi-reference
PX-478, an inhibitor of hypoxia-inducible factor-1alpha, enhances radiosensitivity of prostate carcinoma cells
10.1002/ijc.23807 · doi-reference
Development of HIF-1 inhibitors for cancer therapy
10.1111/j.1582-4934.2009.00876.x · doi-reference
Inhibiting the hypoxia response for cancer therapy: the new kid on the block
10.1158/1078-0432.ccr-09-1650 · doi-reference
Development of novel therapeutic strategies that target HIF-1
10.1517/14728222.10.2.267 · doi-reference
